• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1272088 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
$ E, [- h' P+ }7 Y1 [& K' z2 |- iNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ' j& `8 @" ^# a9 \
+ Author Affiliations/ D1 }. B4 {, W1 ?$ Q$ n% @
( U9 o$ m/ b; N  H
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
9 J' f& J% c1 l1 {% f& ^8 o2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan , B5 \; z2 G7 z
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan $ |) d* L, ^0 e; {0 n
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) K: Q8 ^+ l) e( m1 O9 M
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ( p5 T, u. T8 b% z
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 4 }5 J. B0 k1 L1 P' ]/ G! }7 T1 D
7Kinki University School of Medicine, Osaka 589-8511, Japan
% M  M  y3 X+ D, b$ q8Izumi Municipal Hospital, Osaka 594-0071, Japan
8 N" G! k, b- n9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
5 l4 p7 B% T7 k7 @$ ^. }1 O. aCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 9 @- Z/ s, H1 o
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ) z5 c/ ?0 I: E: L& d$ ^& a

" O* T% k* }2 _* G% F! [  b
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
' C( t( v8 A/ R- Y9 o; E) M2 d6 A) M( Q
* j$ I' s% f; g) ^: o5 IAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato + C+ |& q" w# v0 F" _6 ~- i' p
* V' c% Y. u- ], d5 |- h
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
3 _# E( n+ M' W) B# }0 D0 w% t  g% `! w1 ^5 N7 ?# M
Published online on: Thursday, December 1, 2011
% N# f  u" m* U# O9 v! @, d
3 K* R5 A/ L7 o. GDoi: 10.3892/ol.2011.507   P, V! y1 x) ~% v# |

4 E' G/ z6 r4 hPages: 405-410 7 x9 I. U# Z3 K! S' T' h% I

1 l6 W  Z9 F; LAbstract:
! U8 t0 v6 m1 `6 Q" q9 bS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.9 F: D+ q' I: _0 ]7 M: C$ I1 d
1 Y7 C9 l7 I1 f# D; Z; Z
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population1 _/ ]2 ?- U1 Z
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 ( O* e7 g& ?- d9 M% c0 u6 S
+ Author Affiliations
! [4 D3 W) I7 o' O1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu , d  e& V' I2 J# J/ a
2Department of Thoracic Surgery, Kyoto University, Kyoto
# r' s7 o( `* k1 `3 _3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
- \; v( T9 t8 r$ U* c7 V: U&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 4 N4 e" i5 T! Y5 q3 V
Received September 3, 2010. 0 Z' |' k! E, \, I9 Q
Revision received November 11, 2010.
$ w3 l' ?- M& j$ _1 sAccepted November 17, 2010.
$ l+ Q9 Z5 f+ `' ]! |7 L3 lAbstract) @0 l& c( T$ B: |( q
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
/ r/ O& J2 E. n* G5 W' q: jPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 9 q0 o5 }+ H- ~9 _# Y
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. ' i( b# J9 t! n0 W" K
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 8 K+ a, n0 ]' `# D9 C
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
( M7 c0 h( c5 f今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?. ]4 E/ D5 v; E7 e8 P9 |( i
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy5 k" c+ d3 }$ |; q) \& k2 e/ [2 e
http://clinicaltrials.gov/ct2/show/NCT01523587
, N8 a) q5 H! I* v# H" z. W8 c/ F$ c$ |8 z7 o5 ]' e( K! {& ^
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC& U" V2 A3 s) u, A/ i
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 # J1 j. b* Z7 t% U
( Y1 Z* Q5 R1 T# U5 `6 ]+ |
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。; H8 h' o, y- C4 l
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

  U2 D9 G2 S$ W2 g' n% K( a) v没有副作用是第一追求,效果显著是第二追求。
3 p$ M: g. S  _不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表